Phase II trial of cancer vaccine MUC-1 (ImMucin) in patients with multiple myeloma.
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2016
Price : $35 *
At a glance
- Drugs Cancer vaccine MUC-1 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vaxil BioTherapeutics
- 16 Jun 2016 According to a Vaxil BioTherapeutics media release, this trial is planned to launch in 2017.
- 16 Mar 2015 ImMucin has received orphan drug designation from the EMA for multiple myeloma and this study is expected to be initiated in 2015, according to a Vaxil BioTherapeutics media release.
- 23 Oct 2014 New trial record